Cargando…
Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling
This study investigated the antitumor effects of foretinib on triple-negative breast cancer cells MDA-MB-231 xenograft tumors in vivo underlying phosphorylated mesenchymal to epithelial transition (p-MET)/ hepatocyte growth factor (HGF)-related mechanism, as well as its pharmacokinetic characteristi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821162/ https://www.ncbi.nlm.nih.gov/pubmed/36614199 http://dx.doi.org/10.3390/ijms24010757 |
_version_ | 1784865631848366080 |
---|---|
author | Ji, Xiwei Meng, Xiangrui He, Qingfeng Xiang, Xiaoqiang Shi, Yufei Zhu, Xiao |
author_facet | Ji, Xiwei Meng, Xiangrui He, Qingfeng Xiang, Xiaoqiang Shi, Yufei Zhu, Xiao |
author_sort | Ji, Xiwei |
collection | PubMed |
description | This study investigated the antitumor effects of foretinib on triple-negative breast cancer cells MDA-MB-231 xenograft tumors in vivo underlying phosphorylated mesenchymal to epithelial transition (p-MET)/ hepatocyte growth factor (HGF)-related mechanism, as well as its pharmacokinetic characteristics. The MDA-MB-231 human breast cancer cell line was used for in vitro experiments, and the tumor xenograft model was established for in vivo experiments. MDA-MB-231 xenograft mice received oral foretinib (15 or 50 mg/kg/day) or vehicle for 18 days. The xenograft tumors were collected. Protein expressions of p-MET and HGF were examined with Western blotting and immunohistochemical staining. The mRNA expression of MET was examined with real-time PCR. Blood samples were collected from the mice treated with foretinib under different doses of 2, 10, and 50 mg/kg, and the pharmacokinetic profiles of foretinib were evaluated. We found that foretinib treatment caused a significant inhibition in tumor growth in a dose-dependent manner, whereas the continuous administration did not result in weight loss in treated nude mice. In both MDA-MB-231 cells and xenograft tumors, foretinib suppressed the expression of p-MET and HGF. These findings reveal that the decrease of p-MET and HGF may play an important role in the anti-breast cancer properties of foretinib. |
format | Online Article Text |
id | pubmed-9821162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98211622023-01-07 Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling Ji, Xiwei Meng, Xiangrui He, Qingfeng Xiang, Xiaoqiang Shi, Yufei Zhu, Xiao Int J Mol Sci Article This study investigated the antitumor effects of foretinib on triple-negative breast cancer cells MDA-MB-231 xenograft tumors in vivo underlying phosphorylated mesenchymal to epithelial transition (p-MET)/ hepatocyte growth factor (HGF)-related mechanism, as well as its pharmacokinetic characteristics. The MDA-MB-231 human breast cancer cell line was used for in vitro experiments, and the tumor xenograft model was established for in vivo experiments. MDA-MB-231 xenograft mice received oral foretinib (15 or 50 mg/kg/day) or vehicle for 18 days. The xenograft tumors were collected. Protein expressions of p-MET and HGF were examined with Western blotting and immunohistochemical staining. The mRNA expression of MET was examined with real-time PCR. Blood samples were collected from the mice treated with foretinib under different doses of 2, 10, and 50 mg/kg, and the pharmacokinetic profiles of foretinib were evaluated. We found that foretinib treatment caused a significant inhibition in tumor growth in a dose-dependent manner, whereas the continuous administration did not result in weight loss in treated nude mice. In both MDA-MB-231 cells and xenograft tumors, foretinib suppressed the expression of p-MET and HGF. These findings reveal that the decrease of p-MET and HGF may play an important role in the anti-breast cancer properties of foretinib. MDPI 2023-01-01 /pmc/articles/PMC9821162/ /pubmed/36614199 http://dx.doi.org/10.3390/ijms24010757 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ji, Xiwei Meng, Xiangrui He, Qingfeng Xiang, Xiaoqiang Shi, Yufei Zhu, Xiao Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling |
title | Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling |
title_full | Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling |
title_fullStr | Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling |
title_full_unstemmed | Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling |
title_short | Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling |
title_sort | foretinib is effective against triple-negative breast cancer cells mda-mb-231 in vitro and in vivo by down-regulating p-met/hgf signaling |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821162/ https://www.ncbi.nlm.nih.gov/pubmed/36614199 http://dx.doi.org/10.3390/ijms24010757 |
work_keys_str_mv | AT jixiwei foretinibiseffectiveagainsttriplenegativebreastcancercellsmdamb231invitroandinvivobydownregulatingpmethgfsignaling AT mengxiangrui foretinibiseffectiveagainsttriplenegativebreastcancercellsmdamb231invitroandinvivobydownregulatingpmethgfsignaling AT heqingfeng foretinibiseffectiveagainsttriplenegativebreastcancercellsmdamb231invitroandinvivobydownregulatingpmethgfsignaling AT xiangxiaoqiang foretinibiseffectiveagainsttriplenegativebreastcancercellsmdamb231invitroandinvivobydownregulatingpmethgfsignaling AT shiyufei foretinibiseffectiveagainsttriplenegativebreastcancercellsmdamb231invitroandinvivobydownregulatingpmethgfsignaling AT zhuxiao foretinibiseffectiveagainsttriplenegativebreastcancercellsmdamb231invitroandinvivobydownregulatingpmethgfsignaling |